NEW YORK, Jan. 28, 2016 /PRNewswire/ -- This BCC Research report provides an in-depth study of the liquid biopsy diagnostics industry. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. The market sizes are given for the years 2014, 2015 and 2020.
Use this report to:
Analyze the market for liquid biopsy diagnostics in depth.
Gain information on liquid biopsy technologies, clinical applications, industry structure, important liquid biopsy funding initiatives, global markets, patent status and companies.
Learn about some of the top research initiatives that are contributing to liquid biopsy development.
Gain information on various liquid biopsy diagnostics markets, including for reproductive health, cancer and transplant diagnostics
The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.
The cancer application market will increase at a CAGR of 36.2% over the forecast period to grow from $414.5 million in 2015 to $1.9 billion in 2020.
The non-cancer application market as a segment reached $1.2 billion in 2015 and should reach $2.5 billion by 2020 increasing at a CAGR of 15.7%.
STUDY GOALS AND OBJECTIVES
This BCC Research report provides an in-depth study of the liquid biopsy diagnostics industry, an emerging industry with high market potential. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. The market sizes are given for the years 2014, 2015 and 2020.
Market segments that provide exceptional growth opportunities include cancer monitoring and organ transplant surveillance.
The report provides a comprehensive discussion of liquid biopsy technologies, clinical applications, industry structure, important liquid biopsy funding initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts relating to life science tools and diagnostics
REASONS FOR DOING THE STUDY
Traditional biopsy methods are often invasive and uncomfortable, and carry risks of side effects. Liquid biopsy addresses these issues because it is noninvasive and carries little, if any, side effect risks.
With the advent of the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability, and thus is of high interest to the medical community.
Liquid biopsy enabling technologies are rapidly making progress, and this is adding to the market growth momentum. Downstream analysis technologies like next-generation sequencing (NGS) and digital polymerase chain reaction (PCR) are progressing in capabilities, efficiency and costs. Upstream technologies like icrofluidics, cell capture and DNA amplification are also making significant progress.
Based on these trends, liquid biopsy markets are rapidly emerging, and the need for industry and market characterization is great.
Also, liquid biopsy is extending its market penetration into high-volume diagnostics segments, including average risk noninvasive prenatal testing (NIPT) and cancer monitoring.
The outstanding growth potential for liquid biopsy diagnostics makes it particularly timely for doing this report.
Read the full report: http://www.reportlinker.com/p03596607-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001